X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs GSK PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD GSK PHARMA LUPIN LTD/
GSK PHARMA
 
P/E (TTM) x 28.4 59.3 48.0% View Chart
P/BV x 3.0 11.9 24.9% View Chart
Dividend Yield % 0.6 2.4 23.1%  

Financials

 LUPIN LTD   GSK PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
GSK PHARMA
Mar-18
LUPIN LTD/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4652,760 53.1%   
Low Rs7272,040 35.6%   
Sales per share (Unadj.) Rs349.6339.0 103.1%  
Earnings per share (Unadj.) Rs5.641.4 13.4%  
Cash flow per share (Unadj.) Rs29.645.9 64.4%  
Dividends per share (Unadj.) Rs5.0035.00 14.3%  
Dividend yield (eoy) %0.51.5 31.3%  
Book value per share (Unadj.) Rs300.3242.9 123.6%  
Shares outstanding (eoy) m452.0884.70 533.7%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.17.1 44.3%   
Avg P/E ratio x197.257.9 340.3%  
P/CF ratio (eoy) x37.152.3 70.9%  
Price / Book Value ratio x3.69.9 36.9%  
Dividend payout %90.084.5 106.5%   
Avg Mkt Cap Rs m495,502203,280 243.8%   
No. of employees `00017.0NA-   
Total wages/salary Rs m28,6475,234 547.3%   
Avg. sales/employee Rs Th9,273.6NM-  
Avg. wages/employee Rs Th1,681.0NM-  
Avg. net profit/employee Rs Th147.4NM-  
INCOME DATA
Net Sales Rs m158,04228,715 550.4%  
Other income Rs m1,504545 275.7%   
Total revenues Rs m159,54529,260 545.3%   
Gross profit Rs m31,4755,059 622.2%  
Depreciation Rs m10,859380 2,857.6%   
Interest Rs m2,0442 102,175.0%   
Profit before tax Rs m20,0765,222 384.5%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,644178 -8,226.7%   
Tax Rs m2,8851,892 152.5%   
Profit after tax Rs m2,5133,508 71.6%  
Gross profit margin %19.917.6 113.0%  
Effective tax rate %14.436.2 39.7%   
Net profit margin %1.612.2 13.0%  
BALANCE SHEET DATA
Current assets Rs m122,09521,815 559.7%   
Current liabilities Rs m50,95615,999 318.5%   
Net working cap to sales %45.020.3 222.2%  
Current ratio x2.41.4 175.7%  
Inventory Days Days8564 133.0%  
Debtors Days Days12019 641.7%  
Net fixed assets Rs m129,87612,475 1,041.1%   
Share capital Rs m904847 106.8%   
"Free" reserves Rs m134,86619,726 683.7%   
Net worth Rs m135,77120,573 659.9%   
Long term debt Rs m64,2456 1,070,750.0%   
Total assets Rs m263,05439,475 666.4%  
Interest coverage x10.82,612.0 0.4%   
Debt to equity ratio x0.50 162,250.5%  
Sales to assets ratio x0.60.7 82.6%   
Return on assets %1.78.9 19.5%  
Return on equity %1.917.1 10.9%  
Return on capital %3.726.2 14.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,141564 9,422.2%   
Fx outflow Rs m19,3357,429 260.3%   
Net fx Rs m33,807-6,865 -492.4%   
CASH FLOW
From Operations Rs m17,5124,728 370.4%  
From Investments Rs m-14,073-1,042 1,350.7%  
From Financial Activity Rs m-14,921-3,066 486.6%  
Net Cashflow Rs m-11,482620 -1,852.8%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 50.7 0.4%  
Indian inst/Mut Fund % 11.3 10.2 110.8%  
FIIs % 31.9 23.8 134.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 15.4 65.6%  
Shareholders   98,259 102,036 96.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   NOVARTIS  JUBILANT LIFE SCIENCES  BIOCON LTD  IPCA LABS  ALKEM LABORATORIES  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Oct 17, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE LUPIN LTD WITH

MARKET STATS